Hormonal
The metabolically healthy obese (MHO) phenotype is characterized by preserved insulin sensitivity and favorable metabolic markers despite high body fat, primarily driven by reduced visceral and ectopic (liver) fat accumulation and healthy adipose tissue expansion.
If you are obese but metabolically healthy (normal blood pressure, lipids, and insulin sensitivity), your risk profile is significantly better than that of an obese person with metabolic abnormalities. Focus on maintaining this metabolic health through healthy lifestyle habits, as MHO is not a permanent state and conversion to unhealthy status occurs in ~30% of cases over 5-10 years, often due to aging or weight gain.
for a similar total fat mass, MHO individuals present less visceral and ectopic fat, in particular liver steatosis than patients with metabolic abnormalities... The MHO phenotype is also associated with a lower degree of systemic inflammation
Why this rating
Based on multiple conference presentations citing transgenic models, twin studies, and clinical cohorts, though consensus on definition is lacking.
Source
Metabolically healthy and unhealthy obese – the 2013 <scp>S</scp>tock <scp>C</scp>onference report
Dorit Samocha‐Bonet et al. · Obesity Reviews · 2014
DOI 10.1111/obr.12199
More from this paper
- Preserved mitochondrial function and healthy adipose tissue expansion (via angiogenesis and adiponectin secretion) are key mechanisms that prevent ectopic fat storage and insulin resistance in metabolically healthy obese individuals.Good
- Metabolically healthy obese (MHO) is not a stable state; approximately 30% of MHO individuals convert to metabolically unhealthy obese (MUHO) over 5-10 years, primarily due to aging and additional weight gain.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →